Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

Bibliographic Details
Main Authors:	Suzuki, M, Takeda, M, Kito, A, Fukazawa, M, Yata, T, Yamamoto, M, Nagata, T, Fukuzawa, T, Yamane, M, Honda, K, Suzuki, Y, Kawabe, Y
Format:	Online
Language:	English
Published:	Nature Publishing Group 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189930/

Similar Items

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
by: Suzuki, Katsunori, et al.
Published: (2016)

Functional Roles of Electrogenic Sodium Bicarbonate Cotransporter NBCe1 in Ocular Tissues
by: Suzuki, Masashi, et al.
Published: (2012)

Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys
by: Sano, Motoaki, et al.
Published: (2016)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
by: Kaku, Kohei, et al.
Published: (2014)

The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension
by: Hoorn, Ewout J., et al.
Published: (2011)

Sirolimus Induced Phosphaturia is Not Caused by Inhibition of Renal Apical Sodium Phosphate Cotransporters
by: Haller, Maria, et al.
Published: (2012)

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
by: Osorio, Horacio, et al.
Published: (2012)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
by: Poudel, Resham Raj
Published: (2013)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
by: Ferrannini, Giulia, et al.
Published: (2015)

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
by: Kalra, Sanjay, et al.
Published: (2016)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
by: Kalra, Sanjay, et al.
Published: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
by: Reed, James W
Published: (2016)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
by: Kalra, Sanjay, et al.
Published: (2015)

Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
by: Hirose, Sachie, et al.
Published: (2016)

Effects of xylitol on metabolic parameters and visceral fat accumulation
by: Amo, Kikuko, et al.
Published: (2011)

Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide
by: Okuyama-Dobashi, Kaori, et al.
Published: (2015)

Responses of renal hemodynamics and tubular functions to acute sodium–glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats
by: Tuba M. Ansary, et al.
Published: (2017-08-01)

Transport Activity of the Sodium Bicarbonate Cotransporter NBCe1 Is Enhanced by Different Isoforms of Carbonic Anhydrase
by: Schueler, Christina, et al.
Published: (2011)

Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet
by: Nishimura, R., et al.
Published: (2016)

Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J‐STEP/EL): A 12‐week interim analysis
by: Utsunomiya, Kazunori, et al.
Published: (2016)

Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice
by: Atageldiyeva, Kuralay, et al.
Published: (2016)

The Influence of Dietary Fat on Liver Fat Accumulation
by: Green, Charlotte J., et al.
Published: (2014)

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
by: Tahrani, Abd A., et al.
Published: (2011)

Ouabain-insensitive salt and water movements in duck red cells. II. Norepinephrine stimulation of sodium plus potassium cotransport
by: Schmidt III, WF, et al.
Published: (1977)

Sodium-alanine cotransport in renal proximal tubule cells investigated by whole-cell current recording
Published: (1991)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
by: Rosenstock, Julio, et al.
Published: (2012)

Sodium-phosphate cotransport in human red blood cells. Kinetics and role in membrane metabolism
Published: (1988)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
by: Kim, Yoojin, et al.
Published: (2012)

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
by: Ring, Arne, et al.
Published: (2013)

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
by: Ferrannini, Ele, et al.
Published: (2013)

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus
by: Yan, Huan, et al.
Published: (2012)

Modulation of the cardiac sodium/bicarbonate cotransporter by the renin angiotensin aldosterone system: pathophysiological consequences
by: De Giusti, Verónica C., et al.
Published: (2014)

Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis
by: Cardani, Diego, et al.
Published: (2014)

Regulation of the Cardiac Sodium/Bicarbonate Cotransporter by Angiotensin II: Potential Contribution to Structural, Ionic and Electrophysiological Myocardial Remodelling
by: Aiello, Ernesto Alejandro, et al.
Published: (2013)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018-09-01)

Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
by: Shin Kawasoe, et al.
Published: (2017-04-01)

Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
by: Kim A. Connelly, et al.
Published: (2018-07-01)

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
by: Peters, Anne L., et al.
Published: (2015)

Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency
by: Deng, Mei, et al.
Published: (2016)

Erratum: Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
Published: (2016)